Spinogenix is advancing tazbentetol through an Expanded Access Program aimed at ALS patients who are ineligible for clinical trials. This initiative not only addresses an unmet medical need but also positions Spinogenix favorably within the ALS treatment landscape, which is characterized by limited therapeutic options. The program may enhance brand visibility and patient engagement, potentially leading to future market opportunities. Given the increasing prevalence of ALS and the demand for innovative therapies, successful outcomes could attract interest from investors and collaborators, while also providing valuable real-world evidence to support regulatory submissions.